<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00479765</url>
  </required_header>
  <id_info>
    <org_study_id>PR016-CLN-pro002</org_study_id>
    <secondary_id>OGL-109</secondary_id>
    <nct_id>NCT00479765</nct_id>
  </id_info>
  <brief_title>A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma</brief_title>
  <official_title>A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BTG International Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BTG International Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OncoGel™ is a new, experimental drug delivery system that allows the slow continuous release
      of paclitaxel (an approved intravenous anticancer drug), from a gel (ReGel™) over a long
      period of time. The gel will disappear in 4 to 6 weeks as it releases the paclitaxel.

      The purpose of this study is to evaluate the safety and tolerability of OncoGel when placed
      into the tumor resection cavity in the brain following surgical removal of the tumor. Dose
      escalation is conducted by gradually increasing the amount of OncoGel placed in the resection
      cavity in small groups of patients, and watching the patients closely for side effects before
      moving to the next dose level. The study will also test whether OncoGel helps to prevent or
      delay the tumor from regrowing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is for patients with recurrent glioblastoma multiforme. Because most recurrences
      are in the area of the original resection, local delivery of a chemotherapeutic agent may
      prevent or delay additional recurrences. Paclitaxel has demonstrated activity against 9L
      glioma tumor lines, but has poor central nervous system penetration after intravenous
      administration. OncoGel is a new formulation of paclitaxel in a bioerodible gel that can be
      administered directly to the brain, thereby bypassing the blood-brain barrier.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor business decision, not based on safety or efficacy data
  </why_stopped>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurence of Dose-limiting Toxicities (DLTs)</measure>
    <time_frame>8 weeks</time_frame>
    <description>any evidence or sign of a dose-limiting toxicity after administration to determine the maximum tolerated dose (MTD)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <condition>Brain Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OncoGel administered into remaining cavity after surgical resection. Each dose cohort will receive a different volume of OncoGel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OncoGel (ReGel/Paclitaxel)</intervention_name>
    <description>OncoGel administered into cavity after surgical resection of recurrent glioma. Each subject will receive one dose of OncoGel on the day of surgical resection.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 to less than 70 years of age

          -  Radiological evidence on MRI of progressive recurrent malignant glioma that is
             unilateral, unifocal, supratentorial and of the minimum tumor volume as required per
             dose level assignment

          -  Tumor must have a solid contrast enhancing component

          -  Gross total resection &gt;95% of the recurrence must be planned

          -  Must have received prior conventional radiation therapy completed &gt;4 weeks before
             Study Day 1 (ie, day of craniotomy and OncoGel administration)

          -  Previous cytoreductive surgery or biopsy with pathologic diagnosis of glioblastoma
             multiforme

          -  Diagnosis of glioma at the time of debulking surgery for recurrence (by frozen section
             or squash preparation)

          -  Life expectancy &gt; 2 months

          -  KPS greater than or equal to 70

          -  Using appropriate birth control, if female of child-bearing potential;

          -  Able and willing to participate in the study by signing the informed consent document

        Exclusion Criteria:

          -  Contrast-enhancing tumor crossing the midline

          -  Multifocal or non-contiguous tumor resulting in multiple resection cavities

          -  Evidence of tumor dissemination (ependymal, leptomeningeal)

          -  Tumors that result in a lobectomy or after resection leave an insufficient residual
             cavity to receive the expected OncoGel volume

          -  Expected communication between the ventricle and resection cavity that cannot be
             repaired

          -  Involvement of primary sensorimotor cortex in the dominant hemisphere or within 1.5 cm
             of the optic chiasm, either optic nerve or any other cranial nerve

          -  Significantly increased intracranial pressure

          -  Received any type of stereotactic radiosurgery or brachytherapy with the exception of
             a stereotactic radiosurgery boost as part of the initial radiation therapy

          -  History of seizures refractory to two or more anticonvulsant medications
             co-administered at therapeutic levels

          -  Impaired organ function as evidenced by clinically significant laboratory parameters
             including but not limited to the following: Hepatic Status: Bilirubin &gt;2.0 mg/dL;
             Aspartate transaminase (AST) &gt;2.5 times the normal limit; Alanine aminotransferase
             (ALT) &gt;2.5 times the normal limit. Hematopoietic Status: Absolute neutrophil count
             (ANC) &lt;1500mm3; Platelet count &lt;100,000/mm3; Hemoglobin &lt; 10 g/dL. Hemostatic:
             Prothrombin Time (PT) or INR above normal range; Partial Thromboplastin Time (PTT)
             above normal range; Bleeding Time outside normal range (if performed by hospital).
             Renal Status: Serum creatinine &gt;2 mg/dL.

          -  Contraindication to MRI

          -  Receipt any chemotherapeutic agent within 28 days of Study Day 1 or nitrosourea within
             6 weeks of Study Day 1

          -  Received any intracerebral investigational agent

          -  Receipt of another investigational drug or device within 28 days of the planned
             surgery

          -  Known history of allergy to paclitaxel or any other component of OncoGel

          -  Pregnant or lactating

          -  Concurrent life-threatening disease

          -  Any medical condition or other circumstance that, in the opinion of the Investigator,
             would make the subject unlikely or unable to successfully complete the study, or would
             interfere with analysis of study results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maciej S Lesniak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Chicago Brain Tumor Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2007</study_first_submitted>
  <study_first_submitted_qc>May 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2007</study_first_posted>
  <results_first_submitted>April 17, 2014</results_first_submitted>
  <results_first_submitted_qc>April 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 15, 2014</results_first_posted>
  <last_update_submitted>April 17, 2014</last_update_submitted>
  <last_update_submitted_qc>April 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2014</last_update_posted>
  <responsible_party>
    <name_title>Claire Daugherty, Clinical Project Manager</name_title>
    <organization>Protherics</organization>
  </responsible_party>
  <keyword>glioblastoma multiforme</keyword>
  <keyword>recurrent</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Phase 2</keyword>
  <keyword>Phase I</keyword>
  <keyword>Phase II</keyword>
  <keyword>brain</keyword>
  <keyword>cancer</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>intracranial</keyword>
  <keyword>tumor</keyword>
  <keyword>local</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>brain tumor</keyword>
  <keyword>brain cancer</keyword>
  <keyword>glioma</keyword>
  <keyword>OncoGel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>OncoGel</title>
          <description>OncoGel administered into remaining cavity after surgical resection. Each dose cohort will receive a different volume of OncoGel
OncoGel (ReGel/Paclitaxel): OncoGel administered into cavity after surgical resection of recurrent glioma. Each subject will receive one dose of OncoGel on the day of surgical resection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>study terminated</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Four subjects were dosed with 5% Oncogel prior to study termination.</population>
      <group_list>
        <group group_id="B1">
          <title>OncoGel 5mL</title>
          <description>OncoGel 5 mL administered into remaining cavity after surgical resection. Each dose cohort will receive a different volume of OncoGel
OncoGel (ReGel/Paclitaxel): OncoGel administered into cavity after surgical resection of recurrent glioma. Each subject will receive one dose of OncoGel on the day of surgical resection.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="46" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Occurence of Dose-limiting Toxicities (DLTs)</title>
        <description>any evidence or sign of a dose-limiting toxicity after administration to determine the maximum tolerated dose (MTD)</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OncoGel 5mL</title>
            <description>OncoGel 5 mL administered into remaining cavity after surgical resection. Each dose cohort will receive a different volume of OncoGel
OncoGel (ReGel/Paclitaxel): OncoGel administered into cavity after surgical resection of recurrent glioma. Each subject will receive one dose of OncoGel on the day of surgical resection.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurence of Dose-limiting Toxicities (DLTs)</title>
          <description>any evidence or sign of a dose-limiting toxicity after administration to determine the maximum tolerated dose (MTD)</description>
          <units>dose limiting toxicities</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>OncoGel 5mL</title>
          <description>OncoGel 5 mL administered into remaining cavity after surgical resection. Each dose cohort will receive a different volume of OncoGel
OncoGel (ReGel/Paclitaxel): OncoGel administered into cavity after surgical resection of recurrent glioma. Each subject will receive one dose of OncoGel on the day of surgical resection.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>subdural hematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Claire Daugherty</name_or_title>
      <organization>BTG International Inc</organization>
      <phone>610-278-1660</phone>
      <email>claire.daugherty@btgplc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

